Enhances Focus on Revision Arthroplasty with Pilot Launch of Three New Revision Systems in Fourth Quarter

Exactech, Inc. (Nasdaq: EXAC), a worldwide developer and producer of bone and joint restoration products, announced today the successful first surgeries performed with its new revision knee system. Designed to provide a reproducible surgical technique for treating complex revision total knee replacement patients, the system includes a comprehensive implant offering and ergonomically designed instrumentation. Pilot launch is scheduled through the remainder of the year with full market availability in the United States in 2016.

Orthopaedic surgeons Bernard Stulberg, MD, of St. Vincent Charity Medical Center in Cleveland, Ohio, and Geoffrey Westrich, MD, of Hospital for Special Surgery in New York, NY performed the first cases using the knee system during the past week.

"I was honored and pleased to be the first to use the new instruments and devices for revision of a failed knee replacement,” Dr. Stulberg said. “The implant provided excellent early stability and kinematics, and allowed my patient to be discharged to home within two days. The instruments were intuitive, comfortable to use and allowed for a straightforward and accurate approach to assessing bone loss, and for re-establishing proper implant position, alignment and stability. This was a satisfying experience that I believe many surgeons will be able to share, as this innovative new implant and instrument system helps them to address the myriad of problems encountered in revision total knee replacement.”

The revision knee system addresses Exactech’s knee design philosophy of delivering “performance over time” in a streamlined procedure. The evolutionary design incorporates clinically recognized, patented designs and proprietary net compression molded polyethylene. Combined with modern, user friendly instrumentation, the revision knee system is designed for operating room efficiency and reproducible outcomes, case after case.

“In developing Exactech’s new revision knee system, the team focused on reproducibility and efficiency while also leveraging proven design elements that have delivered excellent long-term clinical outcomes,” Dr. Westrich said. “The first case was a great success.”

According to Exactech CEO David Petty, the knee system is one of three new revision implant and instrumentation systems that are making their clinical debut. The company is also piloting its new revision hip stem and a shoulder humeral reconstruction prosthesis. “We are reaffirming our commitment to revision arthroplasty,” Petty said. “It is our goal to deliver patient-driven solutions that allow surgeons to provide a wide continuum of care. Clinical use of this knee system is the culmination of years of collaboration with world-renowned revision total knee surgery experts.”

Exactech worked closely with a design team of experienced revision knee surgeons to develop this revision system: Bernard Stulberg, MD, St. Vincent Charity Medical Center; Geoffrey Westrich, MD, Hospital for Special Surgery; Daniel C. Allison, MD, Cedars-Sinai Medical Center; James Huddleston, MD, Stanford Medicine; Richard Parkinson, MB ChB, FRCS, Spire Murrayfield Hospital Wirral, United Kingdom.

The new Exactech revision knee system is indicated for use in skeletally mature patients undergoing surgery for total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems; this device is also indicated for revision of failed previous reconstruction where sufficient bone stock and soft tissue integrity are present.

About Exactech Knee

The Exactech knee system combines clinically proven implants with personalized surgical workflows for reproducible outcomes, case after case. With a design developing for more than four decades and excellent clinical and laboratory results, surgeons can have every confidence in a system that delivers “performance over time”.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Exactech, Inc.Investor contactsJody Phillips, 352-377-1140Executive Vice President of Finance &Chief Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins, 305-451-1888E-mail: EXAC@hawkassociates.comorMedia contactPriscilla Bennett, 352-377-1140Vice President, Corporate & Marketing Communication

Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Exactech, Inc. (delisted) Charts.
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Exactech, Inc. (delisted) Charts.